Kenneth C. Cundy, SVP, Preclinical Development at XENOPORT INC (XNPT), sold 300 shares at $27.01 ($8K) on 2009-02-02, disclosed to the SEC on 2009-02-03.
Scheduled sale ($8k) by SVP, Preclinical Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.90 | 100 | $3K | 33.3% |
| 2 | $26.94 | 100 | $3K | 33.3% |
| 3 | $27.01 | 100 | $3K | 33.4% |
| Total | $26.95 avg | 300 | $8K | 100% |
| Filing → |
| CWBR | SELL | 2020-08-10 | $19K | — | Filing → |
| CWBR | SELL | 2020-06-17 | $24K | — | Filing → |
| CWBR | SELL | 2020-05-18 | $26K | — | Filing → |